Zai Lab (ZLAB) Set to Announce Quarterly Earnings on Thursday

Key Points

• Zai Lab is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $0.5642 per share and revenue of approximately $108.83 million.
• The company reported a $0.50 per-share loss and $106.31 million in revenue in its previous quarter, while analysts project full-year and next-year losses of roughly $2.37 and $2.36 per share, respectively.
• Wall Street’s consensus rating is “Moderate Buy”, with an average price target of $37.25 versus the stock’s reported opening price of $23.04; however, insiders have sold shares totaling about $235,145 over the past 90 days.

Zai Lab (NASDAQ:ZLAB - Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.5642) per share and revenue of $108.83 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The firm had revenue of $106.31 million during the quarter. On average, analysts expect Zai Lab to post ($2.37) EPS for the current fiscal year and ($2.36) EPS for the next fiscal year.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $23.04 on Thursday. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -13.47 and a beta of 0.73. The stock's fifty day moving average price is $25.10 and its two-hundred day moving average price is $20.92. Zai Lab has a one year low of $15.96 and a one year high of $27.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ZLAB shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Zai Lab in a research report on Tuesday. Citigroup raised their price target on shares of Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Zai Lab from a "sell" rating to a "hold" rating in a research report on Saturday, September 26th. Zacks Research upgraded shares of Zai Lab from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.25.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 8,506 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the transaction, the director owned 41,931 shares in the company, valued at $1,048,275. This trade represents a 16.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 9,385 shares of company stock worth $235,145. 4.88% of the stock is owned by company insiders.

Zai Lab Company Profile

Zai Lab Ltd. NASDAQ: ZLAB is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.